We also determined the lethal activity of cotreatment with a range of concentrations of ABBV-075 and A-1210477 in five of the samples (#14−18) of PD CD34+ AML BPCs (Figs. S4G and S10). This evidence concerns the gene CD34 and acute myeloid leukemia.